| rivastigmine transdermal / Generic mfg. |
2020-005633-33: Prediction of ECT treatment response and reduction of Cognitive Side-effects using EEG and Rivastigmine |
|
|
| Not yet recruiting | 4 | 100 | Europe | Rivastigmine, Transdermal patch, Rivastigmine | University Medical Center Groningen, Netherlands Organization for Scientific Research | A depressive disorder, Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
RADIC, ChiCTR1900026313: Rivastigmine transdermal patch in Alzheimer's DIsease: a real-world evaluation of Caregiver burden |
|
|
| Recruiting | 4 | 532 | | Rivastigmine transdermal patch ;Oral anti-dementia drugs | Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, individual | Alzheimer's disease | | | | |
PRECISER, NCT05768126: Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine |
|
|
| Recruiting | 4 | 100 | Europe | Rivastigmine Transdermal Product, Sham | UMC Utrecht, ZonMw: The Netherlands Organisation for Health Research and Development, St. Antonius Hospital, Tergooi Hospital | Depressive Disorder | 12/25 | 01/26 | | |
2018-003219-23: CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson’s Disease) |
|
|
| Not yet recruiting | 3 | 600 | Europe | Rivastigmin Luye Transdermal Patches - 4.6mg/24h, Rivastigmine Luye Transdermal Patch- 9.5mg/24h, Rivastigmine transdermal system 13.3 mg/24 h, N/A, RIV-TDS 13.3 mg/24 h, Transdermal patch, Rivastigmin Luye Transdermal Patches - 4.6mg/24h, Rivastigmine Luye Transdermal Patch- 9.5mg/24h | University of Bristol, National Institute for Health Research, Health Assessment Technology Programme | This trial will investigate the effectiveness of Rivastigmine on prevention of falls in patients with Parkinson's disease, Parkinson's Disease is a condition in which the nervous system is damaged which leads to a loss of control of the muscles that control walking and balance., Diseases [C] - Nervous System Diseases [C10] | | | | |
| Active, not recruiting | 3 | 600 | Europe | Rivastigmine Transdermal System, Placebo Transdermal System | University of Bristol, Royal United Hospitals Bath NHS Foundation Trust | Parkinson Disease | 05/24 | 02/25 | | |
NCT05883124: Rivastigmine Bioequivalence Trial With Multiple Applications of Transdermal Patches (9.5 mg/24 h) |
|
|
| Completed | 1 | 38 | Europe | Rivastigmine twice-weekly 9,5 mg/24 h, Exelon® 9.5 mg/24 h | SocraTec R&D GmbH | Bioequivalence | 06/23 | 07/23 | | |
NCT05853341: Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h) |
|
|
| Completed | 1 | 48 | Europe | RID-TDS 13.3 mg/24 h, Exelon® 13.3 mg/24 h | Luye Pharma Group Ltd., SocraTec R&D GmbH, SocraMetrics GmbH | Healthy | 07/23 | 07/23 | | |
NCT04366518: Toward a Computationally-Informed, Personalized Treatment for Hallucinations |
|
|
| Recruiting | 1 | 35 | US | Rivastigmine Transdermal System, Scopolamine, Placebo Patch | Yale University, National Institute of Mental Health (NIMH) | Hallucinations, Auditory, Psychosis | 08/32 | 08/32 | | |
ChiCTR-TRC-10001037: Efficacy of Rivastigmine Transdermal Patch in Dementia Patients who do not benefit from Oral Acetylcholinesterase Inhibitors (AChIs) |
|
|
| Completed | N/A | 50 | | Exelon Patch (rivastigmine transdermal system) | NA; Level of the institution：, CUHK Neurology Research Fund | Dementia patients who are indicated for Acetylcholinesterase Inhibitors | | | | |